‘Die Trying’ – Friday’s VICE Episode on HBO to Address ALS

‘Die Trying’ – Friday’s VICE Episode on HBO to Address ALS

“Die Trying”, this Friday’s episode of HBO’s edgy half-hour newsmagazine series VICE, is about ALS and hosted by the show’s Senior Associate Editor Angelina Fanous who is battling the disease. A preview trailer can be viewed at: https://als.vice.com/. Living with ALS, Egyptian-born Fanous is now focusing on…

6 ALS Therapies to Improve Quality of Life

Amyotrophic lateral sclerosis (ALS) is a disease that progressively shuts down your muscles by attacking certain cells in the brain and spinal cord needed to keep our muscles moving. Eventually, patients will lose their mobility, have trouble moving, walking, swallowing and even breathing. There is no known cure for ALS…

What is ALS?

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS usually affects people between the ages of 40 and 70, but this doesn’t mean that it cannot be diagnosed at other ages. Unfortunately, around 20,000 American citizens are estimated to develop the disease…

Research Points to Neurodegenerative Consequences, Such as ALS, of Toxoplasma Gondii Infection

Researchers at the University of California-Riverside have shown, for the first time, that infection from the common parasite Toxoplasma gondii disrupts neurotransmitter glutamate function in the brain, potentially leading to neuronal death and neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), in individuals predisposed to such conditions. The research paper, “…

What is Lou Gehrig’s Disease or ALS?

In this video from teleemg’s channel, watch Dr. Joe F. Jabre, neurologist, discuss some facts and useful information about amyotrophic lateral disease (ALS), also known as Lou Gehrig’s disease, such as its causes, symptoms and signs, life expectancy and how it can be…

Cerebrospinal Fluid of ALS Patients Has Reduced Levels of Anti-Inflammatory Protein, Revealing Potential New Therapeutic Target

Researchers from the Institute of Drug Research at the The Hebrew University in Israel have revealed that patients with amyotrophic lateral sclerosis (ALS) have low levels of the anti-inflammatory protein alpha-1-antitrypsin (AAT) in their cerebrospinal fluid (CSF). The findings have been published in the Journal of Neuroinflammation in the study…

EMA Recommends Filing for Masitinib Conditional Marketing Authorization to Treat ALS

Rapporteurs appointed by the European Medicines Agency (EMA) have recommended that AB Science SA’s combined treatment ‘masitinib with riluzole’ in the treatment of adults with amyotrophic lateral sclerosis (ALS) should be filed for conditional marketing authorization. AB Science specializes in developing and marketing protein kinase inhibitors (PKIs), a class of targeted proteins…